Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced G3 Non-small Cell Gastroenteropancreatic Neuroendocrine Carcinomas

Trial Profile

Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced G3 Non-small Cell Gastroenteropancreatic Neuroendocrine Carcinomas

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Capecitabine (Primary) ; Temozolomide (Primary) ; Cisplatin; Etoposide
  • Indications Neuroendocrine carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2016 Trial design presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 05 Jan 2016 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
    • 05 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top